A randomized phase II, open-label and multicenter study of combination regimens of bortezomib at two doses by subcutaneous injection for newly diagnosed multiple myeloma patients

• Published in: Journal of cancer research and clinical oncology Vol. 145; no. 9; pp. 2343 - 2355
• Main Authors: Li, Feng, Yao, Fu-Sheng, Zhu, Xi-Jun, Gu, Wei-Ying, Wang, Xiao-Hua, Chen, Bing, Huang, Dong-Ping, Ding, Jia-Hua, Wu, Tian-Qin, Zhu, Yan, Zhao, Qian, Tang, Yu-Mei, Song, Ping, Zhou, Xiao-Gang, An, Zhi-Ming, Guo, Xing, Wang, Xu-Li, Zhong, Long, Xie, Xiao-Bao, Zhai, Yong-Ping
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.09.2019; Springer Nature B.V
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Bortezomib; Bortezomib - administration & dosage; Bortezomib - adverse effects; Cancer Research; ClinicalTrials.gov; Cyclophosphamide; Cyclophosphamide - administration & dosage; Cyclophosphamide - adverse effects; Dexamethasone; Dexamethasone - administration & dosage; Dexamethasone - adverse effects; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematology; Humans; Injections, Subcutaneous; Internal Medicine; Male; Medicine; Medicine & Public Health; Middle Aged; Multiple myeloma; Multiple Myeloma - diagnosis; Multiple Myeloma - drug therapy; NCT02086942; Oncology; Original Article – Clinical Oncology; Risk groups; Targeted cancer therapy; Teniposide - administration & dosage; Treatment Outcome; Different doses; Efficacy; Bortezomib; Subcutaneous injection; Multiple myeloma

Purpose Combinations of bortezomib (Velcade), cyclophosphamide and dexamethasone have shown significant efficacy and safety for patients of newly diagnosed multiple myeloma (NDMM). In this study, we compared the efficacy and safety of modified VCD regimens with novel changes in bortezomib dose and s...